OLGA JOSEPHINE JACQUES

Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine BRONX, NY NPI 1508213992

General Payments — all program years on this page

$1,320.80

  • Category: General Payments
  • Program years: PY2019–2024
  • Record count: 60
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $451.96 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $451.9619

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Lilly USA, LLC $211.3310
Astellas Pharma US Inc $103.023
GlaxoSmithKline, LLC. $52.802
Exact Sciences Corporation $49.842
Novo Nordisk AS $17.851
Phathom Pharmaceuticals, Inc. $17.121

By program year

Program yearAmountRecords
2019 $54.262
2020 $87.544
2021 $179.269
2022 $149.237
2023 $398.5519
2024 $451.9619

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1096936615 Novo Nordisk Inc $17.85 08/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114479864 Exact Sciences Corporation $19.63 02/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114479871 Exact Sciences Corporation $30.21 04/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1115975669 GlaxoSmithKline, LLC. $26.40 10/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116404411 GlaxoSmithKline, LLC. $26.40 04/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135180966 Lilly USA, LLC $23.33 07/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135180968 Lilly USA, LLC $1.00 03/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135250044 Lilly USA, LLC $33.07 05/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135255954 Lilly USA, LLC $14.23 06/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135267755 Lilly USA, LLC $25.28 03/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135267760 Lilly USA, LLC $28.98 11/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135297342 Lilly USA, LLC $16.99 03/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135299181 Lilly USA, LLC $20.60 05/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135309803 Lilly USA, LLC $20.80 07/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135309808 Lilly USA, LLC $27.05 02/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139410125 Astellas Pharma US Inc $34.72 10/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139431954 Astellas Pharma US Inc $34.34 11/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139453672 Astellas Pharma US Inc $33.96 12/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151075868 Phathom Pharmaceuticals, Inc. $17.12 10/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.